research Abstracts
Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
Search
for
Sort by
Research
330-360 / 1000+ resultsresearch PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.
research Gefitinib-induced hair alterations: Figure 1
Gefitinib can cause slower, finer, brittle, and curly scalp hair.
research Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
Gefitinib can cause hair loss without scarring.
research ダブルストロボレンジファインダの開発(特別講演)(画像センシングおよび一般)
Some prostate cancers have gene changes that may affect treatment with certain drugs.
research Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
research Epigenetic Regulation of Medulloblastoma Proliferation by Finasteride-Induced Modulation of BTG2 and CD244 Gene Methylation
Finasteride may help treat childhood brain tumors by activating certain genes.
research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
research New agents for cancer chemoprevention
Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
Gefitinib can cause hair and eyebrow darkening.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Hair Growth After Gefitinib Treatment
A man's bald spot grew hair after starting cancer treatment with gefitinib.
research BIOBRAN MGN-3
Biobran MGN-3 reduces chemotherapy side effects and improves quality of life for breast cancer patients.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies
Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research DEFINING THE ROLE OF ABI1 GENE IN PROSTATE CANCER PROGRESSION AND TREATMENT RESISTANCE
The ABI1 gene contributes to prostate cancer progression and treatment resistance.
research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research IMPACT OF BIOMARKER IN PREDICATIVE TO RESPONSE ADJUVANT CHEMOTHERAPY AND OVERALL SURVIVAL IN FEMALES INFECTED WITH BREAST CANCER: A REVIEW ARTICLES
Certain genes can predict how well breast cancer patients respond to chemotherapy.
research Therapeutic Potential of Brassinosteroids in Biomedical and Clinical Research
Brassinosteroids may be useful in treating cancer, infections, and other diseases.